This real-world (n=269) analysis of esketamine (Spravato) use finds nearly 50% of patients had their first pharmacy claim approved. Of those approved, 45% had eight or more treatment sessions (as recommended), though spread over 85 days (versus 28 per the label). Patients had lower health utilization, but this could be due to factors outside of the esketamine treatment (e.g. regression to the mean).
- Published
- Journal
- Journal of Medical Economics
- Authors
- Caron-Lapointe, G., Joshi, K., Pilon, D., Shah, A., Teeple, A., Zhdanava, M.